Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 2 May 2016 |
| Novo Nordisk increased adjusted operating profit by 10% in local currencies in the first quarter of 2016 | 29 Apr 2016 |
| Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial | 28 Apr 2016 |
| Novo Nordisk A/S - Share repurchase programme | 28 Apr 2016 |
| Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2016 | 28 Apr 2016 |
| Novo Nordisk A/S - Reduction of the share capital | 18 Apr 2016 |